Cargando…

CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery

While myriad molecular formats for bispecific antibodies have been examined to date, the simplest structures are often based on the scFv. Issues with stability and manufacturability in scFv-based bispecific molecules, however, have been a significant hindrance to their development, particularly for...

Descripción completa

Detalles Bibliográficos
Autores principales: Fennell, Brian J, McDonnell, Barry, Tam, Amy Sze Pui, Chang, Lijun, Steven, John, Broadbent, Ian D, Gao, Huilan, Kieras, Elizabeth, Alley, Jennifer, Luxenberg, Deborah, Edmonds, Jason, Fitz, Lori J, Miao, Wenyan, Whitters, Matthew J, Medley, Quintus G, Guo, Yongjing J, Darmanin-Sheehan, Alfredo, Autin, Bénédicte, Shúilleabháin, Deirdre Ní, Cummins, Emma, King, Amy, Krebs, Mark RH, Grace, Christopher, Hickling, Timothy P, Boisvert, Angela, Zhong, Xiaotian, McKenna, Matthew, Francis, Christopher, Olland, Stephane, Bloom, Laird, Paulsen, Janet, Somers, Will, Jensen, Allan, Lin, Laura, Finlay, William JJ, Cunningham, Orla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3896602/
https://www.ncbi.nlm.nih.gov/pubmed/23995618
http://dx.doi.org/10.4161/mabs.26201
_version_ 1782300102001426432
author Fennell, Brian J
McDonnell, Barry
Tam, Amy Sze Pui
Chang, Lijun
Steven, John
Broadbent, Ian D
Gao, Huilan
Kieras, Elizabeth
Alley, Jennifer
Luxenberg, Deborah
Edmonds, Jason
Fitz, Lori J
Miao, Wenyan
Whitters, Matthew J
Medley, Quintus G
Guo, Yongjing J
Darmanin-Sheehan, Alfredo
Autin, Bénédicte
Shúilleabháin, Deirdre Ní
Cummins, Emma
King, Amy
Krebs, Mark RH
Grace, Christopher
Hickling, Timothy P
Boisvert, Angela
Zhong, Xiaotian
McKenna, Matthew
Francis, Christopher
Olland, Stephane
Bloom, Laird
Paulsen, Janet
Somers, Will
Jensen, Allan
Lin, Laura
Finlay, William JJ
Cunningham, Orla
author_facet Fennell, Brian J
McDonnell, Barry
Tam, Amy Sze Pui
Chang, Lijun
Steven, John
Broadbent, Ian D
Gao, Huilan
Kieras, Elizabeth
Alley, Jennifer
Luxenberg, Deborah
Edmonds, Jason
Fitz, Lori J
Miao, Wenyan
Whitters, Matthew J
Medley, Quintus G
Guo, Yongjing J
Darmanin-Sheehan, Alfredo
Autin, Bénédicte
Shúilleabháin, Deirdre Ní
Cummins, Emma
King, Amy
Krebs, Mark RH
Grace, Christopher
Hickling, Timothy P
Boisvert, Angela
Zhong, Xiaotian
McKenna, Matthew
Francis, Christopher
Olland, Stephane
Bloom, Laird
Paulsen, Janet
Somers, Will
Jensen, Allan
Lin, Laura
Finlay, William JJ
Cunningham, Orla
author_sort Fennell, Brian J
collection PubMed
description While myriad molecular formats for bispecific antibodies have been examined to date, the simplest structures are often based on the scFv. Issues with stability and manufacturability in scFv-based bispecific molecules, however, have been a significant hindrance to their development, particularly for high-concentration, stable formulations that allow subcutaneous delivery. Our aim was to generate a tetravalent bispecific molecule targeting two inflammatory mediators for synergistic immune modulation. We focused on an scFv-Fc-scFv format, with a flexible (A(4)T)(3) linker coupling an additional scFv to the C-terminus of an scFv-Fc. While one of the lead scFvs isolated directly from a naïve library was well-behaved and sufficiently potent, the parental anti-CXCL13 scFv 3B4 required optimization for affinity, stability, and cynomolgus ortholog cross-reactivity. To achieve this, we eschewed framework-based stabilizing mutations in favor of complementarity-determining region (CDR) mutagenesis and re-selection for simultaneous improvements in both affinity and thermal stability. Phage-displayed 3B4 CDR-mutant libraries were used in an aggressive “hammer-hug” selection strategy that incorporated thermal challenge, functional, and biophysical screening. This approach identified leads with improved stability and >18-fold, and 4,100-fold higher affinity for both human and cynomolgus CXCL13, respectively. Improvements were exclusively mediated through only 4 mutations in V(L)-CDR3. Lead scFvs were reformatted into scFv-Fc-scFvs and their biophysical properties ranked. Our final candidate could be formulated in a standard biopharmaceutical platform buffer at 100 mg/ml with <2% high molecular weight species present after 7 weeks at 4 °C and viscosity <15 cP. This workflow has facilitated the identification of a truly manufacturable scFv-based bispecific therapeutic suitable for subcutaneous administration.
format Online
Article
Text
id pubmed-3896602
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-38966022014-01-29 CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery Fennell, Brian J McDonnell, Barry Tam, Amy Sze Pui Chang, Lijun Steven, John Broadbent, Ian D Gao, Huilan Kieras, Elizabeth Alley, Jennifer Luxenberg, Deborah Edmonds, Jason Fitz, Lori J Miao, Wenyan Whitters, Matthew J Medley, Quintus G Guo, Yongjing J Darmanin-Sheehan, Alfredo Autin, Bénédicte Shúilleabháin, Deirdre Ní Cummins, Emma King, Amy Krebs, Mark RH Grace, Christopher Hickling, Timothy P Boisvert, Angela Zhong, Xiaotian McKenna, Matthew Francis, Christopher Olland, Stephane Bloom, Laird Paulsen, Janet Somers, Will Jensen, Allan Lin, Laura Finlay, William JJ Cunningham, Orla MAbs Report While myriad molecular formats for bispecific antibodies have been examined to date, the simplest structures are often based on the scFv. Issues with stability and manufacturability in scFv-based bispecific molecules, however, have been a significant hindrance to their development, particularly for high-concentration, stable formulations that allow subcutaneous delivery. Our aim was to generate a tetravalent bispecific molecule targeting two inflammatory mediators for synergistic immune modulation. We focused on an scFv-Fc-scFv format, with a flexible (A(4)T)(3) linker coupling an additional scFv to the C-terminus of an scFv-Fc. While one of the lead scFvs isolated directly from a naïve library was well-behaved and sufficiently potent, the parental anti-CXCL13 scFv 3B4 required optimization for affinity, stability, and cynomolgus ortholog cross-reactivity. To achieve this, we eschewed framework-based stabilizing mutations in favor of complementarity-determining region (CDR) mutagenesis and re-selection for simultaneous improvements in both affinity and thermal stability. Phage-displayed 3B4 CDR-mutant libraries were used in an aggressive “hammer-hug” selection strategy that incorporated thermal challenge, functional, and biophysical screening. This approach identified leads with improved stability and >18-fold, and 4,100-fold higher affinity for both human and cynomolgus CXCL13, respectively. Improvements were exclusively mediated through only 4 mutations in V(L)-CDR3. Lead scFvs were reformatted into scFv-Fc-scFvs and their biophysical properties ranked. Our final candidate could be formulated in a standard biopharmaceutical platform buffer at 100 mg/ml with <2% high molecular weight species present after 7 weeks at 4 °C and viscosity <15 cP. This workflow has facilitated the identification of a truly manufacturable scFv-based bispecific therapeutic suitable for subcutaneous administration. Landes Bioscience 2013-11-01 2013-08-21 /pmc/articles/PMC3896602/ /pubmed/23995618 http://dx.doi.org/10.4161/mabs.26201 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Report
Fennell, Brian J
McDonnell, Barry
Tam, Amy Sze Pui
Chang, Lijun
Steven, John
Broadbent, Ian D
Gao, Huilan
Kieras, Elizabeth
Alley, Jennifer
Luxenberg, Deborah
Edmonds, Jason
Fitz, Lori J
Miao, Wenyan
Whitters, Matthew J
Medley, Quintus G
Guo, Yongjing J
Darmanin-Sheehan, Alfredo
Autin, Bénédicte
Shúilleabháin, Deirdre Ní
Cummins, Emma
King, Amy
Krebs, Mark RH
Grace, Christopher
Hickling, Timothy P
Boisvert, Angela
Zhong, Xiaotian
McKenna, Matthew
Francis, Christopher
Olland, Stephane
Bloom, Laird
Paulsen, Janet
Somers, Will
Jensen, Allan
Lin, Laura
Finlay, William JJ
Cunningham, Orla
CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery
title CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery
title_full CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery
title_fullStr CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery
title_full_unstemmed CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery
title_short CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery
title_sort cdr-restricted engineering of native human scfvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery
topic Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3896602/
https://www.ncbi.nlm.nih.gov/pubmed/23995618
http://dx.doi.org/10.4161/mabs.26201
work_keys_str_mv AT fennellbrianj cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery
AT mcdonnellbarry cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery
AT tamamyszepui cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery
AT changlijun cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery
AT stevenjohn cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery
AT broadbentiand cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery
AT gaohuilan cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery
AT kieraselizabeth cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery
AT alleyjennifer cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery
AT luxenbergdeborah cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery
AT edmondsjason cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery
AT fitzlorij cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery
AT miaowenyan cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery
AT whittersmatthewj cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery
AT medleyquintusg cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery
AT guoyongjingj cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery
AT darmaninsheehanalfredo cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery
AT autinbenedicte cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery
AT shuilleabhaindeirdreni cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery
AT cumminsemma cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery
AT kingamy cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery
AT krebsmarkrh cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery
AT gracechristopher cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery
AT hicklingtimothyp cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery
AT boisvertangela cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery
AT zhongxiaotian cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery
AT mckennamatthew cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery
AT francischristopher cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery
AT ollandstephane cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery
AT bloomlaird cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery
AT paulsenjanet cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery
AT somerswill cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery
AT jensenallan cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery
AT linlaura cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery
AT finlaywilliamjj cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery
AT cunninghamorla cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery